Sofinnova Partners
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
Tenpoint Therapeutics unlocks a £170m Series B from investors to rejuvenate vision in the aging eye
Tenpoint Therapeutics develops treatments for age-related eye conditions. Its products are designed to address presbyopia and other vision issues through clinically developed ophthalmic therapies.
T-Therapeutics secures £24m Series A extension with Tencent and BGF to develop T cell receptor therapeutics for cancer and autoimmune disease
T-Therapeutics develops next-generation T cell receptor therapies designed to target cancer and autoimmune disease, advancing bispecific molecules that selectively remove disease-driving immune cells while preserving healthy function.
Elevara raises £50m Series A led by Forbion and Sofinnova Partners to develop therapies for rheumatoid arthritis
Elevara develops oral therapies for rheumatoid arthritis by targeting synovial fibroblasts rather than the immune system, aiming to improve remission rates in chronic inflammatory disease.
Latent Labs raises £40m Series A led by Radical Ventures and Sofinnova Partners to advance AI protein design
Latent Labs develops AI foundation models for generative protein design, enabling biotech and pharmaceutical teams to computationally design new antibodies, enzymes and therapeutics more efficiently.
More venture news
- 1 Apr 2026
Sona secures a £34m Series B led by N47 for workforce management software focussed on frontline businesses
Series BEnterprise - 26 Mar 2026
Giraffe360Giraffe360 secures a £7.5m Series B led by Cipio Partners for real estate marketing tech
Series BProperty - 18 Feb 2026
FYLD secures a £30m Series B led by Energy Impact Partners to monitor high-risk infrastructure fieldwork with intelligence platform
Series BIndustrial
